More than 98% of the human genome consists of noncoding sequences. The importance of these has been emphasized by genome-wide association studies (GWAS), which have identified many thousands of common genetic variants associated with human traits and disease susceptibility, the vast majority of which localize to the noncoding genome. In addition, as the cost of whole genome sequencing has dropped dramatically, clinical genomes have proliferated. A major bottleneck in realizing the potential of precision medicine and capitalizing on knowledge afforded by GWAS is the inability to understand and predict the functional consequences of perturbation of the noncoding genome. Up until recently, studies of the noncoding genome have been limited to ectopic heterologous reporter assays, correlative biochemical studies, or laborious knockout experiments in model organisms. Advances in genome editing have enabled facile disruption of human noncoding sequences in chromatinized cellular contexts. Recently we have developed a technique, Cas9-mediated in situ saturating mutagenesis, which allows the high-throughput and high-resolution perturbation of noncoding sequences. We hypothesize that only by perturbation in the appropriate chromatin and cellular environment can the requirement of noncoding sequences be established. In this proposal we describe comprehensive studies to characterize essential noncoding sequences required for erythropoiesis as marked by naturally occurring trait- associated genetic variation. Erythropoiesis is a particularly apt system to investigate noncoding genetic determinants given its predominantly cell-intrinsic nature, direct clinical relevance, and the availability of high- quality human genetic data, extensive chromatin maps, and faithful tissue culture models. With these studies, we will perturb trait-associated enhancers as well as non-enhancer noncoding elements to reveal minimal critical sequences required for erythropoiesis. We will introduce several technical advances, including utilization of alternative nucleases for pooled screening, haplotype-aware guide RNA design, predictions of on- target efficiency and off-target potential, and nuclease target deep sequencing, to approach nucleotide resolution determination of critical sequences. We will utilize bioinformatic, biochemical, and genome editing methods to define key trans-acting factors interacting with the essential cis-acting sequences. The overall goal will be to develop improved models of noncoding sequence function by iterative experimental testing and analytic refinement. These studies are intended to yield an improved understanding of blood cell development, identify novel rational targets for blood disorders, and illuminate fundamental mechanisms of gene regulation and trait heritability.

Public Health Relevance

Most of the common genetic variants associated with human diseases are found in the portions of the human genome that do not code for genes, yet the function of these noncoding sequences remains poorly understood. This proposal describes innovative genome editing methodologies to discover the precise noncoding sequences required for red blood cell development. The project seeks to understand and predict noncoding sequence function to enable precision medicine.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
NIH Director’s New Innovator Awards (DP2)
Project #
1DP2HL137300-01
Application #
9168558
Study Section
Special Emphasis Panel (ZRG1-MOSS-C (56)R)
Program Officer
Hanspal, Manjit
Project Start
2016-09-30
Project End
2021-06-30
Budget Start
2016-09-30
Budget End
2021-06-30
Support Year
1
Fiscal Year
2016
Total Cost
$2,655,000
Indirect Cost
$1,155,000
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Gehrke, Jason M; Cervantes, Oliver; Clement, M Kendell et al. (2018) An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities. Nat Biotechnol 36:977-982
Gundry, Michael C; Dever, Daniel P; Yudovich, David et al. (2017) Technical considerations for the use of CRISPR/Cas9 in hematology research. Exp Hematol 54:4-11
Lessard, Samuel; Gatof, Emily Stern; Beaudoin, Mélissa et al. (2017) An erythroid-specific ATP2B4 enhancer mediates red blood cell hydration and malaria susceptibility. J Clin Invest 127:3065-3074
Canver, Matthew C; Bauer, Daniel E; Orkin, Stuart H (2017) Functional interrogation of non-coding DNA through CRISPR genome editing. Methods 121-122:118-129
Canver, Matthew C; Lessard, Samuel; Pinello, Luca et al. (2017) Variant-aware saturating mutagenesis using multiple Cas9 nucleases identifies regulatory elements at trait-associated loci. Nat Genet 49:625-634